Self-Treatment Company Restructures Segment Performance After Major Impairment Loss

Perrigo Company plc filed historical segment information for fiscal 2024 and 2025, recast under its new segment reporting framework, along with reconciliations to non-GAAP measures. The disclosure presented net sales and adjusted operating profit by Self Care, Specialty Care, Infant Formula, and Other & Unallocated segments, and it detailed key adjustments—including intangible asset amortization, one-time litigation charges, restructuring costs, infant formula–related expenses, and asset impairments. Notably, the 2025 figures reflect approximately $1.3 billion (roughly KRW 1.8 trillion) in goodwill impairments—beyond impairments on assets held for sale related to the Richard Bitner business and the Prevacid brand—and a $33.6 million (about KRW 47 billion) impairment on the equity-method investment in Kazumira LLC. As a result, reported operating profit was substantially below the adjusted amount.

On May 6, Perrigo reported first-quarter 2026 results, highlighting continued market-share gains in consumer self-care products, and later announced the sale of its derma-cosmetics business for €305.6 million (approximately KRW 460 billion) to reduce debt. In its full-year 2025 announcement, the company also outlined plans to transition to a product-centric segment structure and realign its performance metrics accordingly starting in 2026.

Headquartered in Dublin, Ireland, Perrigo is a global consumer self-care company supplying over-the-counter pharmaceuticals, non-prescription health and wellness products, infant formula and nutritional items, and oral and skin care products, primarily in North America and Europe. Against a backdrop of rising healthcare costs and growing self-medication demand, the company continues to reshape its business around its store-brand self-care portfolio to capitalize on the expanding consumer health and wellness market.